Eveline M Delemarre
Overview
Explore the profile of Eveline M Delemarre including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
472
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Obodai E, Terstappen J, Mensah J, Versnel A, Antwi C, Bont L, et al.
BMJ Glob Health
. 2025 Mar;
10(3).
PMID: 40037906
Background: Global health clinical research is commonly led by high-income countries (HICs) as low- and middle-income countries (LMICs) face barriers to participate, including lack of financial and human capacity and...
2.
Terstappen J, Delemarre E, Versnel A, White J, Derrien-Colemyn A, Ruckwardt T, et al.
J Infect Dis
. 2024 Jul;
230(1):e93-e101.
PMID: 39052716
Background: The key correlate of protection of respiratory syncytial virus (RSV) vaccines and monoclonal antibodies (mAbs) is virus neutralization, measured via sera obtained through venipuncture. Dried blood obtained with a...
3.
van Eijs M, Ter Linde J, Baars M, Amini M, Lacle M, Brand E, et al.
iScience
. 2023 Sep;
26(10):107891.
PMID: 37766980
Colitis is a prevalent adverse event associated with immune checkpoint inhibitor (ICI) therapy with similarities to inflammatory bowel disease. Incomplete mechanistic understanding of ICI colitis curtails evidence-based treatment. Given the...
4.
Niewold P, Dijkstra D, Cai Y, Goletti D, Palmieri F, van Meijgaarden K, et al.
Sci Rep
. 2023 Jul;
13(1):11617.
PMID: 37464009
Tuberculosis (TB) is a prevalent disease causing an estimated 1.6 million deaths and 10.6 million new cases annually. Discriminating TB disease from differential diagnoses can be complex, particularly in the...
5.
Bos J, Groen E, Budding K, Delemarre E, Goedee H, Knol E, et al.
J Neurol Sci
. 2023 Jul;
451:120692.
PMID: 37422959
Objective: Antibody- and complement-mediated peripheral nerve inflammation are central in the pathogenesis of MMN. Here, we studied innate immune responses to endotoxin in patients with MMN and controls to further...
6.
von Richthofen H, Westerlaken G, Gollnast D, Besteman S, Delemarre E, Rodenburg K, et al.
J Immunol
. 2023 Jan;
210(4):389-397.
PMID: 36637221
Signal inhibitory receptor on leukocytes-1 (SIRL-1) is an immune inhibitory receptor expressed on human granulocytes and monocytes that dampens antimicrobial functions. We previously showed that sputum neutrophils from infants with...
7.
Streng B, Bont M, Delemarre E, Binnendijk R, Smit G, Den Hartog G, et al.
J Infect Dis
. 2022 Jun;
226(4):673-677.
PMID: 35748853
Clinical Trials Registration: NCT05145348.
8.
Wennink R, Ayuso V, Tao W, Delemarre E, de Boer J, Kuiper J
Transl Vis Sci Technol
. 2022 Feb;
11(2):4.
PMID: 35103800
Purpose: To identify a serum biomarker signature that can help predict response to conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy in pediatric noninfectious uveitis. Methods: In this case-control cohort study,...
9.
Hensgens M, Delemarre E, Drylewicz J, Voortman M, Krol R, Dalm V, et al.
Rheumatology (Oxford)
. 2022 Jan;
61(10):4087-4096.
PMID: 35048953
Objectives: The presence of melanoma differentiation-associated protein 5 (MDA5) antibodies in patients with DM is associated with the development of a rapidly progressive interstitial lung disease (RPILD), unresponsive to conventional...
10.
Delemarre E, van Hoorn L, Bossink A, Drylewicz J, Joosten S, Ottenhoff T, et al.
Front Immunol
. 2021 Oct;
12:725447.
PMID: 34691031
Introduction: There is an urgent medical need to differentiate active tuberculosis (ATB) from latent tuberculosis infection (LTBI) and prevent undertreatment and overtreatment. The aim of this study was to identify...